Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Arcutis Biotherapeutics (ARQT) stock in plain English

Free brief · no signupStart here
ARQTPublished Nov 15, 2026
Arcutis Biotherapeutics Inc
Healthcare · Biotechnology
Sells topical cream and foam formulations of roflumilast to treat plaque psoriasis and seborrheic dermatitis.
Assets:
Zoryve product lineapproved cream and foam formulations of roflumilast
California headquartersleased offices and development space in Westlake Village
Targeted pipelineclinical programs evaluating topical therapies for eczema and alopecia
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

60
OPS ScoreOperating finances
Latest quote
-1.59%$27.17
$3.44B
126.0×
$509.00M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 15, 2026Quotes updated Nov 20, 04:10 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was ARQT. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Arcutis Biotherapeutics (ARQT) do?

Arcutis Biotherapeutics Inc (ARQT) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells topical cream and foam formulations of roflumilast to treat plaque psoriasis and seborrheic dermatitis. Develops topical non-steroidal treatments to address chronic immune-mediated skin diseases. It is worth $3.44B on the market and sold $509.00M over the last year.

Market cap
$3.44B
P/E ratio
126.0×
Annual sales
$509.00M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 15, 2026

Brands and businesses behind ARQT

  • Zoryve: This topical medication generates revenue by selling prescription cream and foam to treat chronic inflammatory skin conditions.

ARQT’s flags, in plain English

Each flag is a number from Arcutis Biotherapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 15, 2026.

Wide Gross Margin

Gross margin of 91.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earnings Jumping

Profits up 312.1% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Stupid Cash

Can pay this year's bills 2.9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Priced for Perfection

Priced at 126 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about ARQT

How big is Arcutis Biotherapeutics?

Arcutis Biotherapeutics’ market cap is $3.44B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $509.00M: what customers paid the company over the last year, before any costs.

What is ARQT’s P/E ratio?

ARQT’s P/E ratio is 126.0×. Investors pay about 126.0 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with ARQT?

The business relies on a single active molecule, roflumilast, for all commercial product sales. That is one risk on Arcutis Biotherapeutics’ card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Arcutis Biotherapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. ARQT’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card